Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease.
about
Combined aclidinium bromide and long-acting beta 2 -agonist for COPDPharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells.Umeclidinium for the treatment of chronic obstructive pulmonary disease.Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.QVA149 (indacaterol/glycopyrronium) for the treatment of chronic obstructive pulmonary disease.Focusing the mechanism of action to dissect the different treatments of respiratory allergy.Olodaterol + tiotropium bromide for the treatment of chronic obstructive pulmonary disease.Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update.Aclidinium bromide inhalation powder for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease including chronic bronchitis and emphysema.Tiotropium formulations and safety: a network meta-analysisThe novel compound Sul-121 inhibits airway inflammation and hyperresponsiveness in experimental models of chronic obstructive pulmonary disease.Effects of chronic treatment with the new ultra-long-acting β2 -adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling.The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis.Indacaterol for the treatment of chronic obstructive pulmonary disease.Muscarinic Receptor Antagonists.Olodaterol + tiotropium bromide for the treatment of COPD.Intestinal Epithelial Wnt Signaling Mediates Acetylcholine-Triggered Host Defense against Infection.
P2860
Q24187613-19FEDDE0-D89C-4041-804D-ADC048F17563Q37001907-42EBEB52-0311-4DBD-92EE-80A05537B310Q38259862-7ABC857C-10C3-42E6-99AD-C230013E3D68Q38266325-FF220E8C-6CFF-481C-A05B-2B70D2E45878Q38406157-F6D980AB-166A-446D-AF2F-60D187ED3C2DQ38542919-5DCFD083-4557-4E23-9D05-A6F06A6C513CQ38570714-A0C28844-BE0A-4DB6-AFB4-C2B0745BC915Q38740756-A6C6E316-3483-456C-B374-4091E3B623CBQ38754002-189266FA-8E53-41D8-9806-4E23629D2C59Q38783067-0FCA4299-628D-422A-A6F8-93B372F1F4F3Q39137733-12A4892C-99B4-4125-A9AD-FD52463F73E4Q39733325-EE67D462-094F-40B9-8CF0-92150E95ECAFQ42114497-478D5E64-840E-46BE-8C59-167D4457EC8FQ47177016-58A920A6-F6A3-48F8-8FB0-F13C805F72C8Q48059168-264E5E87-E171-4154-85D3-F0FD770E6D31Q51432583-3D44B337-E704-483E-B7B6-48F0170972C5Q51545895-7D9E3A7A-1B5A-4B48-8766-3FC9B3BFBC38Q54210129-D08AB3F9-B1EA-4BB1-B3C3-39923478B2E8
P2860
Muscarinic receptor antagonists for the treatment of chronic obstructive pulmonary disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Muscarinic receptor antagonist ...... obstructive pulmonary disease.
@en
type
label
Muscarinic receptor antagonist ...... obstructive pulmonary disease.
@en
prefLabel
Muscarinic receptor antagonist ...... obstructive pulmonary disease.
@en
P2860
P1476
Muscarinic receptor antagonist ...... obstructive pulmonary disease
@en
P2093
Maria Gabriella Matera
Mario Cazzola
P2860
P304
P356
10.1517/14656566.2014.899581
P407
P577
2014-03-26T00:00:00Z